NewAmsterdam Pharma (NASDAQ:NAMS) Short Interest Update

NewAmsterdam Pharma (NASDAQ:NAMS) was the target of a large growth in short interest in November. As of November 30th, there was short interest totalling 2,590,000 shares, a growth of 156.4% from the November 15th total of 1,010,000 shares. Based on an average daily volume of 567,700 shares, the days-to-cover ratio is presently 4.6 days. Approximately 6.0% of the shares of the company are short sold.

NewAmsterdam Pharma Trading Down 1.6 %

Shares of NASDAQ NAMS opened at $24.69 on Friday. The business’s fifty day simple moving average is $20.53 and its 200-day simple moving average is $18.72. NewAmsterdam Pharma has a 12-month low of $9.72 and a 12-month high of $27.29.

Analysts Set New Price Targets

A number of research firms have weighed in on NAMS. Scotiabank upped their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Finally, Piper Sandler reissued an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $36.20.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $25.08, for a total transaction of $834,486.84. Following the sale, the insider now directly owns 11,778,760 shares in the company, valued at $295,411,300.80. This trade represents a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Louise Frederika Kooij sold 45,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 86,803 shares of company stock worth $1,755,307. 19.50% of the stock is owned by corporate insiders.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Banque Cantonale Vaudoise purchased a new stake in NewAmsterdam Pharma in the second quarter valued at $38,000. Quarry LP lifted its holdings in shares of NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC grew its stake in NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after buying an additional 7,199 shares during the last quarter. Bellevue Group AG purchased a new position in NewAmsterdam Pharma during the 3rd quarter worth approximately $128,000. Finally, XTX Topco Ltd acquired a new position in NewAmsterdam Pharma during the third quarter worth approximately $187,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.